All-Oral Treatment Combo for AML Earns FDA Nod

Published Date: 15 May 2026

The combo, decitabine and cedazuridine tablets plus venetoclax, was approved for adults aged 75 and older and adults with comorbidities that preclude intensive induction chemotherapy.

Read Full News

Latest News

Low PSA May Not Fully Predict Survival in Prostate Cancer

A recent post hoc analysis assesses whether PSA changes can predict survival outcomes in patients with metastatic or very high risk nonmetastatic prostate cancer.

Only 1 in 4 Eligible Adults Receive Lung Screening

Complicated eligibility rules, stigma surrounding smoking and lung cancer, and confusion about the screening process continue to keep many high-risk patients from getting screened.

FDA Warns of Secondary Blood Cancer Risk With Tazverik

The FDA says the increased risk of hematologic secondary primary malignancies with tazemetostat now outweighs the benefits of the drug; Ipsen pulls it from the market.

FDA Approves Next-Gen Agent for Mantle Cell Lymphoma

The BCL-2 inhibitor was granted accelerated approval based on findings from the phase 1/2 BGB-11417-201 study.

Early PET May Help Tailor Therapy in Hodgkin Lymphoma

A trial evaluates whether very early FDG PET-guided treatment adaptation after one cycle of brentuximab vedotin-based chemotherapy improves outcomes in Hodgkin lymphoma.

When Healthcare Chatbots Fall Short of Human Connection

Researchers report that digital monitoring tools may improve symptom tracking, but nurses face added demands linked to alert verification and patient support.

Todays Updates

Inside OCT and IVUS: AI’s New Edge in PCI

From automatic calcium and lipid detection to post-stent expansion checks, learn how AI helps close the gap between novice and expert and why that matters for outcomes.

Hormone Therapy and Thrombosis: What Clinicians May Miss?

Route of administration, patient history, and formulation choice may shape thrombotic risk more than clinicians previously recognized.

When Does a Tick Bite Need Antibiotics?

The guidance varies depending on the tick and whether it is in endemic area for illnesses like Lyme disease.

Liver & Colorectal Conditions: How New Data Will Impact Care

In this DDW 2026 update, Dr David Johnson reviews key advances in cirrhosis care, GLP-1 benefits, earlier HCC detection, colorectal cancer risks, and IL-23-targeted IBD therapies.

Lipid Guidelines: Four Major Concerns

Too many Class I recommendations lacking supporting data from randomized trials and intellectual conflicts of interest are among John Mandrola’s complaints about the ACC/AHA guidelines on dyslipidemia.

In-Office Nitrous Oxide Linked to Fewer OR Ob/Gyn Procedures

In addition to reducing OR burden and its accompanying costs, offering nitrous oxide for in-office procedures can be easier for patients.

Optimal Sleep May Lower Dementia Risk in Focal Epilepsy

Optimal sleep duration is tied to better cognition and a lower risk for dementia in adults with focal epilepsy than in healthy individuals, new research shows.

Todays Updates

Inside OCT and IVUS: AI’s New Edge in PCI

From automatic calcium and lipid detection to post-stent expansion checks, learn how AI helps close the gap between novice and expert and why that matters for outcomes.

Hormone Therapy and Thrombosis: What Clinicians May Miss?

Route of administration, patient history, and formulation choice may shape thrombotic risk more than clinicians previously recognized.

When Does a Tick Bite Need Antibiotics?

The guidance varies depending on the tick and whether it is in endemic area for illnesses like Lyme disease.

Liver & Colorectal Conditions: How New Data Will Impact Care

In this DDW 2026 update, Dr David Johnson reviews key advances in cirrhosis care, GLP-1 benefits, earlier HCC detection, colorectal cancer risks, and IL-23-targeted IBD therapies.

Lipid Guidelines: Four Major Concerns

Too many Class I recommendations lacking supporting data from randomized trials and intellectual conflicts of interest are among John Mandrola’s complaints about the ACC/AHA guidelines on dyslipidemia.

In-Office Nitrous Oxide Linked to Fewer OR Ob/Gyn Procedures

In addition to reducing OR burden and its accompanying costs, offering nitrous oxide for in-office procedures can be easier for patients.

Optimal Sleep May Lower Dementia Risk in Focal Epilepsy

Optimal sleep duration is tied to better cognition and a lower risk for dementia in adults with focal epilepsy than in healthy individuals, new research shows.

Latest News

A recent post hoc analysis assesses whether PSA changes can predict survival outcomes in patients with metastatic or very high risk nonmetastatic prostate cancer.

Complicated eligibility rules, stigma surrounding smoking and lung cancer, and confusion about the screening process continue to keep many high-risk patients from getting screened.

The FDA says the increased risk of hematologic secondary primary malignancies with tazemetostat now outweighs the benefits of the drug; Ipsen pulls it from the market.

The BCL-2 inhibitor was granted accelerated approval based on findings from the phase 1/2 BGB-11417-201 study.

A trial evaluates whether very early FDG PET-guided treatment adaptation after one cycle of brentuximab vedotin-based chemotherapy improves outcomes in Hodgkin lymphoma.

Researchers report that digital monitoring tools may improve symptom tracking, but nurses face added demands linked to alert verification and patient support.

News All Time

Liquid Biopsies Cut EBV Burkitt Lymphoma Time to Diagnosis

Broader implementation would require substantial investment, but long-term dividends of liquid biopsy analysis in the region could affect diagnosis and care of much more than just this cancer.

Can Exercise Extend Survival After Breast Cancer?

A ‘target trial’ emulation study suggests that regular exercise can help breast cancer survivors live longer.

High Fruit, Veggie Diet Tied to Early-Onset Lung Cancer?

Counterintuitive findings hint that diets rich in fruit, vegetables, and whole grains may increase the risk of lung cancer in young nonsmokers, but experts are skeptical.

Can Alternating Venetoclax Regimens Improve AML Outcomes?

A phase 2 study investigates the combination of cladribine plus low-dose cytarabine and venetoclax alternating with azacitidine plus venetoclax for newly diagnosed acute myeloid leukemia.

Photopenia on [18F]FDG PET/CT Predicts Benign Renal Lesions

Photopenia in high CT density renal lesions on [18F]FDG PET/CT scans shows a high negative predictive value for excluding malignancy.

Vepdegestrant Earns FDA Nod for ESR1-Mutated Breast Cancer

Approval was based on findings from the phase 3 VERITAC-2 trial showing significantly improved PFS for patients with ESR1-mutated disease.

Which Risk Model Better Identifies High-Risk Smoldering MM?

A cohort study compares the distribution and progression risk among individuals classified as having high-risk smoldering multiple myeloma by the AQUILA trial inclusion criteria vs 2/20/20 risk model.

EMA Recommends Generic in Advanced/Metastatic Breast Cancer

Palbociclib slows cancer cell proliferation in patients with HR+/HER2- locally advanced or metastatic breast cancer.

ICIs Show High Responses in Mediastinal B-Cell Lymphoma

Pembrolizumab and nivolumab show favorable response rates with or without consolidation therapy.

CAR-T Induces Deep, Durable Remission in Smoldering Myeloma

In a pilot study — the first to test CAR-T therapy in smoldering multiple myeloma — patients with high-risk disease remained MRD-negative for more than 15 months. But is it a cure?

‘Bar Code’ Biopsy From RNA Could Guide Precision Oncology

New research shows how certain orphan noncoding RNA — oncRNA — can be predictable enough to be a ‘bar code’ identifying specific cancers. Liquid biopsy could be next.

CD39 Blockade Shows Potential in Early-Stage Lung Cancer

A single-arm study hints at an uptick in pathologic complete responses when a CD39 blocker is added to perioperative durvalumab and chemotherapy for NSCLC.

Dasatinib Fails to Improve Outcomes in CBF-AML

A phase 3 study investigates the outcomes associated with intensive chemotherapy with or without dasatinib in core-binding factor acute myeloid leukemia.

Measurable Residual Disease Predicts Real-World AML Relapse

A study of a real-world population underscores measurable residual disease thresholds indicative of the risk for relapse in NPM1-mutated AML, suggesting guidance in treatment decisions.

Can Oncotype Predict Recurrence Risk in Older BC Patients?

A recent study assesses whether Oncotype DX can predict local recurrence risk in older, lower-risk patients with breast cancer who omit adjuvant radiation.

Is Vitamin D a Key to Better Breast Cancer Survival?

A prospective study links sufficient vitamin D levels at the time of breast cancer diagnosis to improved overall survival.

Recommended News For You

New target points to combination therapy for thwarting multidrug resistance in cancer treatment

Implant-based reconstruction linked to increased risk of breast lymphomas

Thriving while surviving: Understanding the social needs of cancer survivors

Targeted First-Line Combo Approved for EGFR-Mutated Lung Cancer

EBCC: European Breast Cancer Conference

From Pathology to Precision: The Story of Leukemia Therapy

When Healthcare Chatbots Fall Short of Human Connection

Recommended Articles For You

Revolutionizing Cancer Treatment: Advances in Immunotherapy and Cell Therapy 

Understanding Waldenstrom Macroglobulinemia - A Comprehensive Guide  

How AI is Transforming Diagnostics, Drug Discovery, and Personalized Oncology 

Hemoglobin C: Understanding its Role in Sickle Cell Disease 

Whats more on Hidoc Dr.

Medical Updates
KOL Videos
Surveys
Events

Daily news to keep you up to date

Gain valuable insights with our in-depth KOL Video discussions

Participate and win cash vouchers

Get updates on the latest events happening around the world
Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Reducing social media to an hour a day boosts young people's self-image.

2.

ICIs Show High Responses in Mediastinal B-Cell Lymphoma

3.

Modified personalized cancer vaccine generates powerful immune response

4.

In Acute Leukemia With Heavily Pretreated Patients, Menin Inhibitor Yields 63 Percent ORR.

5.

After three years, responses to mounetuzumab in follicular lymphoma are still stable.

1.

Empowering Lung Cancer Diagnosis Through the Synergy of Advanced Technologies and Artificial Intelligence

2.

Revolutionizing Oncology: AI in Radiology, Machine Learning in Pathology, and Deep Learning for Cancer Detection

3.

Emerging Therapies and Technologies Reshaping Oncology: Innovations and Impact in 2025

4.

Can We Repurpose BV-CHP for Better Outcomes in Peripheral T-Cell Lymphoma?

5.

Understanding Bone Metastases: How Long Can Someone Live When Cancer Spreads To The Bones?

1.

International Lung Cancer Congress®

2.

Genito-Urinary Oncology Summit 2026

3.

Future NRG Oncology Meeting

4.

ISMB 2026 (Intelligent Systems for Molecular Biology)

5.

Annual International Congress on the Future of Breast Cancer East

1.

Untangling The Best Treatment Approaches For ALK Positive Lung Cancer - Part VIII

2.

Efficient Management of First line ALK-rearranged NSCLC - Part VI

3.

The Era of Targeted Therapies for ALK+ NSCLC: A Paradigm Shift

4.

Efficient Management of First line ALK-rearranged NSCLC - Part VII

5.

Pazopanib Takes Center Stage in Managing Renal Cell Carcinoma - Part III

Fastest Growing Medical Platform for Doctors

Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801

Phone :
+1-415-463-3094

Email :
anishagadia@hidoc.co

Quick Links

Drug DatabaseDrug InteractionDiseases Database
KOL VideosKnowledge HubQuizzes
Medical UpdatesEventsAbout Us

© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
Home
Profile
Login
bot